Cherian John, MD
Internal Medicine · Burgettstown, PANPI 1891792099
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 838 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 54 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 838 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Pfizer$870
- Novartis$862
- Amgen$829
- Novo Nordisk$813
- Johnson & Johnson$672
- plus $9K from 48 others
What the payments were for
- Speaking & faculty fees$220%
- Travel & lodging$5003%
- Food & beverage$13,79196%
- Education$1271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- remede System$500
How this compares
$14,441 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 909 | $456,953 |
| XareltoRivaroxaban | 247 | $195,927 |
| EntrestoSacubitril/Valsartan | 155 | $113,461 |
| JardianceEmpagliflozin | 131 | $100,299 |
| OzempicSemaglutide | 87 | $96,468 |
| JanuviaSitagliptin Phosphate | 181 | $79,171 |
| FarxigaDapagliflozin Propanediol | 93 | $75,791 |
| Ambrisentan | 11 | $72,941 |
| XifaxanRifaximin | 17 | $59,767 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $53,245 |
| MounjaroTirzepatide | 38 | $39,028 |
| Repatha SureclickEvolocumab | 55 | $35,618 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 50 | $32,066 |
| BrilintaTicagrelor | 114 | $30,025 |
| TrulicityDulaglutide | 28 | $23,269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $870 | $456,953909 claims |
| Johnson & JohnsonXarelto | $672 | $195,927247 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $1,878 | $137,883257 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $553 | $115,084144 claims |
| NovartisEntresto | $862 | $113,461155 claims |
| Novo NordiskOzempic | $813 | $96,46887 claims |
| MerckJanuvia | $520 | $79,171181 claims |
| GSKTrelegy Ellipta, Arexvy, Anoro Ellipta | $281 | $77,853135 claims |
| Lilly USA, LLCMounjaro, Trulicity | $343 | $62,29766 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $175 | $59,76717 claims |
| AbbVieQulipta, Linzess | $110 | $28,92738 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $10,1261,135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Burgettstown
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
- Ronak BhimaniNorristown$623K
- David GoldmannPhiladelphia$525K
- Christopher StillDanville$442K
- Jeffrey FreidLower Gwynedd$425K
- Cheryl PegusSpring House$370K
- Eyob FeyssaPhiladelphia$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.